title: Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
abstract: BACKGROUND
  Resveratrol has been reported to lower glycemia in rodent models of type 2 diabetes associated with the stimulation of glucagon-like peptide 1 (GLP-1), which is known to slow gastric emptying, stimulate insulin secretion, and suppress glucagon secretion and energy intake.
  
  
  OBJECTIVE
  We evaluated the effects of 5 wk of resveratrol treatment on GLP-1 secretion, gastric emptying, and glycemic control in type 2 diabetes.
  
  
  METHODS
  Fourteen patients with diet-controlled type-2 diabetes [mean ± SEM glycated hemoglobin (HbA1c): 6.4 ± 0.2% (46.4 ± 2.2 mmol/mol)] received resveratrol (500 mg twice daily) or a placebo over two 5-wk intervention periods with a 5-wk washout period in between in a double-blind, randomized, crossover design. Before and after each intervention period (4 visits), body weight and HbA1c were measured, and patients were evaluated after an overnight fast with a standardized mashed-potato meal labeled with 100 μg (13)C-octanoic acid to measure blood glucose and plasma GLP-1 concentrations and gastric emptying (breath test) over 240 min. Daily energy intake was estimated from 3-d food diaries during the week before each visit.
  
  
  RESULTS
  Fasting and postprandial blood glucose and plasma total GLP-1 as well as gastric emptying were similar at each assessment, and the change in each variable from weeks 0 to 5 did not differ between resveratrol and placebo groups. Similarly, changes in HbA1c, daily energy intake, and body weight after 5 wk did not differ between the 2 treatments.
  
  
  CONCLUSIONS
  In patients with diet-controlled type 2 diabetes, 5 wk of twice-daily 500 mg-resveratrol supplementation had no effect on GLP-1 secretion, glycemic control, gastric emptying, body weight, or energy intake. Our observations do not support the use of resveratrol for improving glycemic control. This trial was registered at www.anzctr.org.au as ACTRN12613000717752.
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Sony S
authors.initials: SS
authors.lastname: Thazhath
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Tongzhi
authors.initials: T
authors.lastname: Wu
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Michelle J
authors.initials: MJ
authors.lastname: Bound
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Helen L
authors.initials: HL
authors.lastname: Checklin
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Scott
authors.initials: S
authors.lastname: Standfield
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia;
authors.forename: Karen L
authors.initials: KL
authors.lastname: Jones
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia; Endocrine and Metabolic Unit and.
authors.forename: Michael
authors.initials: M
authors.lastname: Horowitz
authors.affiliation: Discipline of Medicine, The University of Adelaide, Royal Adelaide Hospital, Adelaide, Australia; Centre of Research Excellence in Translating Nutritional Science to Good Health, The University of Adelaide, Adelaide, Australia; Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, Australia chris.rayner@adelaide.edu.au.
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Rayner
mesh_terms: D000368:Aged; D001786:Blood Glucose / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000178:diet therapy / Q000188:drug therapy; D004311:Double-Blind Method; D002149:Energy Intake / Q000187:drug effects; D005260:Female; D005746:Gastric Emptying / Q000187:drug effects*; D052216:Glucagon-Like Peptide 1 / Q000097:blood* / Q000378:metabolism; D006442:Glycated Hemoglobin / Q000378:metabolism*; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology; D007328:Insulin / Q000097:blood; D008297:Male; D019518:Postprandial Period; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D001786:Blood Glucose; D052216:Glucagon-Like Peptide 1; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin; D000077185:Resveratrol; D013267:Stilbenes
keywords: GLP-1; HbA1c; blood glucose; incretin; resveratrol